Jenny Gonzalez-Armenta

Research Analyst at Leerink Partners

Jenny Gonzalez-Armenta, PhD, is an Equity Research Associate at Leerink Partners specializing in diversified biopharmaceuticals and emerging oncology companies. She covers firms such as Adaptimmune Therapeutics, Bicycle Therapeutics, Genmab, Immatics, and Xenon Pharmaceuticals, consistently contributing to investment recommendations through rigorous fundamental analysis, though specific performance metrics have not been publicly disclosed. Gonzalez-Armenta began her equity research career at Leerink Partners in July 2022, previously working as a Scientist at Jaguar Gene Therapy and as a Research Fellow at Wake Forest School of Medicine, where she focused on drug development and mitochondrial research. She holds a PhD in Molecular Medicine and Translational Science, a BS in Chemistry, and maintains active FINRA registration as a Broker.